182 related articles for article (PubMed ID: 36902476)
21. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
[TBL] [Abstract][Full Text] [Related]
22. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
23. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
[TBL] [Abstract][Full Text] [Related]
24. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
Kalikaki A; Politaki H; Souglakos J; Apostolaki S; Papadimitraki E; Georgoulia N; Tzardi M; Mavroudis D; Georgoulias V; Voutsina A
PLoS One; 2014; 9(8):e104902. PubMed ID: 25137394
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
Messaritakis I; Sfakianaki M; Papadaki C; Koulouridi A; Vardakis N; Koinis F; Hatzidaki D; Georgoulia N; Kladi A; Kotsakis A; Souglakos J; Georgoulias V
Cancer Chemother Pharmacol; 2018 Nov; 82(5):767-775. PubMed ID: 30094617
[TBL] [Abstract][Full Text] [Related]
28. Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer.
Otsuka K; Imai H; Soeda H; Komine K; Ishioka C; Shibata H
Anticancer Res; 2013 Feb; 33(2):625-9. PubMed ID: 23393358
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
30. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.
Brechbuhl HM; Vinod-Paul K; Gillen AE; Kopin EG; Gibney K; Elias AD; Hayashi M; Sartorius CA; Kabos P
Mol Carcinog; 2020 Oct; 59(10):1129-1139. PubMed ID: 32822091
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques.
Kaifi JT; Kunkel M; Das A; Harouaka RA; Dicker DT; Li G; Zhu J; Clawson GA; Yang Z; Reed MF; Gusani NJ; Kimchi ET; Staveley-O'Carroll KF; Zheng SY; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):699-708. PubMed ID: 25807199
[TBL] [Abstract][Full Text] [Related]
32. Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma.
Vismara M; Reduzzi C; Silvestri M; Murianni F; Lo Russo G; Fortunato O; Motta R; Lanzoni D; Giovinazzo F; Miodini P; Pasquali S; Suatoni P; Pastorino U; Roz L; Sozzi G; Cappelletti V; Bertolini G
Clin Chem; 2022 May; 68(5):691-701. PubMed ID: 35304611
[TBL] [Abstract][Full Text] [Related]
33. In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and
El-Heliebi A; Hille C; Laxman N; Svedlund J; Haudum C; Ercan E; Kroneis T; Chen S; Smolle M; Rossmann C; Krzywkowski T; Ahlford A; Darai E; von Amsberg G; Alsdorf W; König F; Löhr M; de Kruijff I; Riethdorf S; Gorges TM; Pantel K; Bauernhofer T; Nilsson M; Sedlmayr P
Clin Chem; 2018 Mar; 64(3):536-546. PubMed ID: 29301749
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
[TBL] [Abstract][Full Text] [Related]
35. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
[TBL] [Abstract][Full Text] [Related]
36. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer.
Brungs D; Lynch D; Luk AW; Minaei E; Ranson M; Aghmesheh M; Vine KL; Carolan M; Jaber M; de Souza P; Becker TM
World J Gastroenterol; 2018 Feb; 24(7):810-818. PubMed ID: 29467551
[TBL] [Abstract][Full Text] [Related]
37. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
38. Biology and significance of circulating and disseminated tumour cells in colorectal cancer.
Steinert G; Schölch S; Koch M; Weitz J
Langenbecks Arch Surg; 2012 Apr; 397(4):535-42. PubMed ID: 22350614
[TBL] [Abstract][Full Text] [Related]
39. Detection and clinical significance of circulating tumour cells in patients with colorectal carcinoma.
Ihnát P; Srovnal J; Hrubovčák J; Martínek L
Rozhl Chir; 2023; 102(10):376-380. PubMed ID: 38302423
[TBL] [Abstract][Full Text] [Related]
40. Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
Chikamatsu K; Tada H; Takahashi H; Kuwabara-Yokobori Y; Ishii H; Ida S; Shino M
Oral Oncol; 2019 Feb; 89():34-39. PubMed ID: 30732956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
